Lexaria Bioscience (LEXX) Net Margin (2017 - 2026)

Lexaria Bioscience has disclosed Net Margin across 10 years of filings, most recently posting 7000.0% for Q1 2026.

• Net Margin for Q1 2026 came in at 7000.0%, up 544828.0% year-over-year; the trailing twelve-month figure through Feb 2026 was 2581.52% (up 79419.0% YoY), and the FY2025 annual result was 1685.74%, up 43648.0% from the prior year.
• Net Margin came in at 7000.0% for Q1 2026 at Lexaria Bioscience, up from 1551.72% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 7000.0% in Q1 2026 to a low of 2389.69% in Q2 2022.
• The 5-year median for Net Margin is 1992.29% (2024), against an average of 2268.23%.
• Across the five-year window, Net Margin jumped 1620164 bps in 2022 and plunged 607809 bps in 2024, its largest moves.
• Lexaria Bioscience's Net Margin stood at 1841.71% in 2022, then sank by 57 bps to 793.24% in 2023, then jumped by 85 bps to 1468.01% in 2024, then rose by 6 bps to 1551.72% in 2025, then surged by 351 bps to 7000.0% in 2026.
• The last three Net Margin figures came in at 7000.0% (Q1 2026), 1551.72% (Q3 2025), and 2183.91% (Q2 2025), per Business Quant data.